Sashidhar Jagdishan’s decision not to seek another term forces India’s largest private lender to navigate leadership transition alongside massive balance sheet digestion.
Curated briefings on corporate finance, technological integration, and executive strategy.
Sashidhar Jagdishan’s decision not to seek another term forces India’s largest private lender to navigate leadership transition alongside massive balance sheet digestion.
The central bank’s August bulletin outlines how domestic consumption and balance-sheet repair continue to shield the economy from persistent external market drag.
Regulatory approval from SEBI sets the stage for Jio Platforms’ long-awaited public listing, testing public market appetite for digital and telecom integration.
Tata Sons holds its board meeting to formalize annual accounts, choosing balance-sheet consolidation over major structural changes.
Official regulatory clearance for the Dixon-Vivo joint venture outlines a pragmatic framework for foreign technology brands manufacturing inside India.
Ather Energy’s launch of the Konarc electric motorcycle and a residential charging platform tackles the core technical and infrastructure limits of two-wheeler adoption.
Shein’s regulatory alignment with Beijing opens the door for a Hong Kong public listing, balancing domestic supply chain oversight with international equity capital.
N Chandrasekaran’s projection that AI agents will match TCS’s physical workforce highlights a fundamental shift in the global IT services delivery model.
BYD’s first-half earnings confirm that relentless domestic retail price cuts are compressing margins, underscoring the financial toll of China’s electric vehicle price war.
Aon’s planned $17 billion takeover of KKR-backed USI signals an aggressive push to consolidate fragmented middle-market commercial insurance brokerage.
U.S. employers are preparing for another year of steep healthcare cost growth, with spending projected to rise by 9.5% in 2027. Higher medical utilization, chronic disease, expensive medicines and increasingly costly claims are forcing companies to reconsider how they finance and structure employee health benefits.
Rising healthcare costs are forcing U.S. employers to reconsider coverage of GLP-1 drugs for weight management. The debate is increasingly about whether the high upfront cost of these medicines can be justified by measurable long-term health and financial benefits.
Bala V Sathyanarayanan_The Most Disruptive Business Leaders to Follow in 2025
Explore long-form reporting and analytical insights that challenge conventional paradigms across global enterprise ecosystems.
“ Progress happens when curious minds ask better questions and build institutions designed to compound value. ”
The Spotlight Editorial ForumComprehensive research and data-backed perspectives on market movements.
Interviews and leadership dialogues with top executives and founders.
Concise briefings on corporate restructuring, capital and governance.
Deep dives into automotive, manufacturing, tech, legal, and healthcare.
In-depth journeys of founders and pioneers transforming industries.
Full magazine issues with curated cover stories and retrospectives.